Related Experiment Video
Updated: Jun 3, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
Published on: May 16, 2012
miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer
Aida Gordanpour1, Aleksandra Stanimirovic, Robert K Nam
1Department of Laboratory Medicine and Pathobiology, University of Toronto, and Sunnybrook Research Institute, Toronto, Canada.
Abstract:
Expression profiling studies using microarrays and other methods have shown that microRNAs (miRNAs) are dysregulated in a wide variety of human cancers. The up-regulation of miR-221 has been reported in carcinomas of the pancreas, breast, and papillary thyroid, as well as in glioblastoma and chronic lymphocytic leukaemia. In prostate cancer, however, down-regulation of miR-221 has been repeatedly confirmed in miRNA expression studies. Also unique to prostate cancer, and found in more than 50% of patients, is the aberrant expression of a known oncogene, the TMPRSS2:ERG fusion. To date, there has been no published study describing miRNA associations in prostate tumours that overexpress the ERG oncogene from the TMPRSS2:ERG fusion transcript. Herein we report that in a large and diverse cohort of prostate carcinoma samples, miR-221 is down-regulated in patients with tumours bearing TMPRSS2:ERG fusion transcripts, thus providing a link between miRNA and gene fusion expression.
Insights
MicroRNAs (miRNAs) like miR-221 are dysregulated in many cancers. This study links down-regulated miR-221 in prostate cancer to the common TMPRSS2:ERG gene fusion.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are frequently dysregulated in human cancers.
- miR-221 is upregulated in various cancers, but downregulated in prostate cancer.
- The TMPRSS2:ERG gene fusion is a hallmark of prostate cancer, found in over 50% of patients.
Purpose of the Study:
- To investigate the association between miR-221 expression and the TMPRSS2:ERG gene fusion in prostate cancer.
- To determine if the common TMPRSS2:ERG fusion influences miR-221 levels in prostate tumors.
Main Methods:
- Analysis of miRNA expression profiles in a large cohort of prostate carcinoma samples.
- Detection of TMPRSS2:ERG fusion transcripts in the same samples.
- Correlation analysis between miR-221 levels and the presence of the TMPRSS2:ERG fusion.
Main Results:
- Downregulation of miR-221 was observed in prostate tumors harboring the TMPRSS2:ERG fusion transcript.
- This association was significant across a diverse cohort of prostate cancer patients.
- This study is the first to report a direct link between miR-221 and the ERG oncogene fusion in prostate cancer.
Conclusions:
- miR-221 downregulation is linked to the TMPRSS2:ERG gene fusion in prostate cancer.
- This finding provides a novel connection between miRNA dysregulation and a key genetic alteration in prostate tumorigenesis.
- Further research may explore the functional implications of this association in prostate cancer development and progression.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Master Transcription Regulators
